Why Can’t I Get Compounded Semaglutide? Understanding the Current Landscape

Last reviewed: May 15, 2026 Last updated: May 15, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Between 2021 and 2023, compounded semaglutide became a lifeline for millions seeking weight loss treatment during widespread brand shortages. Today, the landscape looks remarkably different—and many patients are asking why access has become unpredictable. Understanding the reasons behind this shift helps you make informed decisions about your treatment options.

How Compounded Semaglutide Became a Treatment Option

When Novo Nordisk's Wegovy faced repeated supply constraints between 2021 and early 2023, licensed compounding pharmacies stepped in to meet urgent patient demand. The FDA issued guidance allowing 503A compounders to prepare semaglutide products during this shortage period, which created legal pathways for patient access when brand medications were unavailable.

Compounding pharmacies—facilities that mix, prepare, and package medications under state board oversight—provided a critical service during this gap. PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver medications that follow pharmaceutical-grade standards. This temporary solution became standard practice for thousands of clinics and telemedicine providers nationwide.

The availability of compounded options also sparked broader consumer awareness about personalized weight loss therapy. Patients who might have waited months for brand medications could begin treatment sooner, and this accessibility shifted market expectations permanently. However, the regulatory and supply environment that enabled this expansion has since transformed.

Why Brand Shortages Sparked Compounding Demand

Between 2021 and 2023, Novo Nordisk and Eli Lilly experienced manufacturing bottlenecks that left Wegovy and Mounjaro in critically short supply across the United States. Patients faced waitlists lasting months, and many providers had no way to serve clients seeking evidence-based GLP-1 therapy during this period. This scarcity wasn't temporary—it persisted through multiple production cycles and created a treatment access crisis.

During this shortage window, compounding pharmacies filled approximately 40% of the total GLP-1 prescriptions written in the United States at peak demand. The success of these compounded formulations demonstrated that patients could achieve meaningful weight loss and metabolic improvements using prepared versions of the same active ingredients. This data reinforced the case for expanded compounding access beyond emergency shortage conditions.

Regulatory flexibility during the shortage period allowed clinics and telemedicine platforms to build entire business models around compounded options. As brand supply normalized in late 2023 and into 2024, however, the regulatory framework that permitted this scaling began to shift back toward stricter oversight.

Regulatory Changes Affecting Compounded Semaglutide Access

The FDA's stance on compounded semaglutide has tightened as brand medication supply has improved. In late 2023, the agency clarified that compounding exemptions during shortage periods should not become permanent market replacements. This guidance reflected concerns about quality control, standardization, and the preference for FDA-approved formulations when available from manufacturers.

State pharmacy boards have also implemented stricter requirements for GLP-1 compounding, including enhanced testing protocols, ingredient sourcing documentation, and facility inspections. Some states now limit the quantities that compounders can prepare or require additional prescriber certifications. These regulatory adjustments aim to ensure patient safety but have simultaneously reduced the number of compounding pharmacies able to maintain active GLP-1 production.

Insurance companies and pharmacy benefit managers have begun restricting reimbursement for compounded formulations, preferring brand medications when in stock. This financial pressure has made compounded options less economically viable for some providers, further limiting patient access. PlexusDx continues operating through licensed 503A compounding pharmacies while brand supply remains variable, offering a hedge against future availability disruptions.

Current Factors Behind Compounded Semaglutide Scarcity

Sourcing raw semaglutide powder has become increasingly difficult as manufacturers tighten supply chains and API (active pharmaceutical ingredient) allocations. Compounding pharmacies must contract with licensed suppliers who themselves face allocation restrictions. This creates a bottleneck that makes it impossible for smaller or newer compounding operations to enter the market or scale production.

Quality assurance costs have risen substantially under new regulatory requirements. Compounding pharmacies now invest in enhanced testing, sterility verification, and potency analysis that previous emergency-period protocols did not require. These compliance expenses reduce profit margins and make compounding GLP-1 medications economically challenging compared to higher-volume manufacturing.

Provider demand has shifted as brand supply improved and insurance coverage expanded for FDA-approved semaglutide and tirzepatide. Many clinics that relied on compounded options during shortages have transitioned back to brand formulations or now stock both. This reduced volume from a smaller number of committed providers has made it harder for compounding pharmacies to maintain production efficiency.

What This Means for Your Weight Loss Treatment Options

Access to GLP-1 therapy has not disappeared—it has simply diversified. PlexusDx offers compounded semaglutide injections from $149 monthly, compounded tirzepatide injections from $249 monthly, and oral formulations of both medications at competitive prices. These options remain available without insurance requirements or membership fees across all 50 states.

The Precision Peptide Genetic Test adds personalization to your treatment selection by revealing predispositions in peptide genetic pathways that influence how your body responds to GLP-1 and tirzepatide compounds. Understanding your genetic profile—including variants in GIPR rs1800437, GLP1R rs6923761, and MC4R rs17782313—helps PlexusDx recommend the formulation most likely to deliver results for your specific biology.

For patients prioritizing affordability and non-injection options, the Microdose GLP-1 Protocol starts at $129 monthly, while GLP-Squared (a dual compound approach) ranges from $249. All medications are prepared through licensed 503A compounding pharmacies meeting pharmaceutical standards. The landscape has shifted, but evidence-based treatment remains accessible and personalized.

Frequently Asked Questions About Why Can’t I Get Compounded Semaglutide? Understanding the Current Landscape

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.